Clinical trials: Arterial Inflammation
Coronary Artery Disease, Acute Coronary Syndrome
Colchicine in Percutaneous Coronary Intervention
Inflammation in the arteries of the heart may increase the risk of cardiac death. The proposed research seeks to identify the potential beneficial role of a safe anti-inflammatory medication, colchicine, on reducing damage caused…
- Trial name
- Colchicine-PCI (NCT02594111)
- Where
- United States
- Volunteers
- 714 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder, Depression
Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)
The objective of this clinical trial is to evaluate whether an anti-inflammatory medication, pentoxifylline, reduces depressive symptoms and improves artery function.
- Conditions
- Major Depressive Disorder, Depression, Depressive Symptoms, Cardiovascular Disease (CVD)
- Trial name
- INFLAMED (NCT01625845)
- Testing
- Pentoxifylline, Standard Treatment
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Indiana University
Coronary Artery Disease, Atherosclerosis
Rilonacept to Improve Artery Function in Patients With Atherosclerosis
This study will determine whether an experimental drug called Rilonacept can improve artery function in patients with atherosclerosis, a disease in which fatty deposits in arteries cause the vessels to stiffen, impeding blood…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Inflammation, Endothelial Dysfunction
- Trial name
- NCT00417417
- Testing
- Rilonacept
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Giant Cell Arteritis
Tocilizumab for Patients With Giant Cell Arteritis
Giant-cell arteritis (GCA) is an immune-mediated disease that mostly affects people older than 50 years of age. Glucocorticoid (GC) treatment dramatically alters the symptoms and course of GCA, reducing the likelihood of vascular…
- Trial name
- NCT01450137
- Testing
- Tocilizumab + Glucocorticoids (GCs)
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Disorder of Vitamin C, Atrial Fibrillation
High Dose Vitamin C in Cardiac Surgery Patients
Coronary artery bypass grafting (CABG) is the most common procedure performed by cardiac surgeons. Post-operative atrial fibrillation (AF) is the most common adverse event following CABG, experienced in 20-50% of patients; the…
- Conditions
- Disorder of Vitamin C, Atrial Fibrillation, Complications Due to Coronary Artery Bypass Graft, Heart Valve Disease
- Trial name
- NCT02762331
- Testing
- Ascorbic Acid
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Virginia Commonwealth University
Giant Cell Arteritis, Temporal Arteritis
Ustekinumab for the Treatment of Giant Cell Arteritis
The purpose of this study is to determine whether ustekinumab is effective in the treatment of Giant Cell Arteritis (GCA)
- Conditions
- Giant Cell Arteritis, Temporal Arteritis, Horton's Disease
- Trial name
- UGCA (NCT02955147)
- Testing
- Ustekinumab, Prednisone
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Massachusetts General Hospital
Giant Cell Arteritis
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
Sirukumab is a fully human anti-interleukin-6 (IL-6) immunoglobulin G1-kappa with a high affinity and specificity for binding to the human IL-6 molecule that may have therapeutic benefit in the treatment of giant cell arteritis…
- Trial name
- NCT02531633
- Testing
- Sirukumab, Prednisone
- Where
- 63 sites in United States, Australia and 11 more
- Volunteers
- 161 people
- Sponsor
- GlaxoSmithKline
Sleep Apnea Syndromes, Inflammation
The Effects of Obesity and Obstructive Sleep Apnea on Inflammation and Heart Disease
Obstructive sleep apnea (OSA) is a serious sleep disorder in which a person's breathing is restricted during sleep. Obese individuals with OSA are at an increased risk of inflammation and heart conditions, but it is unknown…
- Trial name
- NCT00371293
- Testing
- Weight Loss Program, CPAP therapy
- Where
- 2 sites in United States
- Volunteers
- 181 people
- Sponsor
- University of Pennsylvania
Coronary Atherosclerosis, Coronary Artery Calcification
Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)
1. Statement of Problem According to the National Fire Protection Association (NFPA), 43.7% of all firefighters that died on the job experienced sudden cardiac death. The job also affords an incredible amount of stress.
- Conditions
- Coronary Atherosclerosis, Coronary Artery Calcification, Coronary Stenosis
- Trial name
- NCT00860847
- Testing
- Aged garlic extract and Coenzyme Q10
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Diabetes, Atherosclerosis
Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy
The study is being performed to determine whether sitagliptin, a dipeptidyl peptidase-4 inhibitor, both acutely and chronically improves blood vessel function.
- Trial name
- NCT01859793
- Testing
- sitagliptin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Medical College of Wisconsin
Giant Cell Arteritis (GCA)
A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper…
- Trial name
- SELECT-GCA (NCT03725202)
- Testing
- Upadacitinib, Corticosteroid (CS)
- Where
- 172 sites in United States, Australia and 22 more
- Volunteers
- 429 people
- Sponsor
- AbbVie
Giant Cell Arteritis
An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of tocilizumab in participants with GCA.
- Trial name
- NCT01791153
- Testing
- Tocilizumab, Prednisone, Corticosteroids
- Where
- 78 sites in United States, Belgium and 12 more
- Volunteers
- 251 people
- Sponsor
- Hoffmann-La Roche
Septic Shock
High MAP in Septic Shock With Hypertension
We hypothesized that the increase in MAP from 65 mmHg to patients' usual level improved sublingual microcirculation.
- Trial name
- NCT01443494
- Testing
- NE
- Where
- China
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Southeast University, China
Atherosclerosis
Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy
This is a study to compare the effect of VIA-2291 vs. Placebo on various inflammatory biomarkers in patients with carotid stenosis scheduled for elective carotid endarterectomy
- Trial name
- NCT00352417
- Testing
- VIA-2291
- Where
- 3 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Tallikut Pharmaceuticals, Inc.
Giant Cell Arteritis
A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis
The primary purpose of this study is to evaluate the efficacy of guselkumab compared to placebo, in combination with a 26-week glucocorticoid (GC) taper regimen, in adult participants with new-onset or relapsing giant cell…
- Trial name
- THEIA (NCT04633447)
- Testing
- Guselkumab
- Where
- 30 sites in United States, Belgium and 7 more
- Volunteers
- 53 people
- Sponsor
- Janssen Research & Development, LLC
Metabolic Diseases, Endocrine System Diseases
Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries
The overall objective of LUCHAR Specific Aims 4.1 and 4.2 is to assess the additional contribution of cardiovascular disease (CVD) risk markers to traditional biomedical risk factors in the prediction of pre-clinical CVD.
- Conditions
- Metabolic Diseases, Endocrine System Diseases, Heart Disease, Vascular Diseases
- Trial name
- NCT00935766
- Testing
- Omega-3
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Denver Health and Hospital Authority
Giant Cell Arteritis
Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA
Primary Objective: To evaluate the efficacy of sarilumab in participants with giant cell arteritis (GCA) as assessed by the proportion of participants with sustained remission for sarilumab compared to placebo, in combination…
- Trial name
- NCT03600805
- Testing
- Sarilumab SAR153191, Prednisone
- Where
- 61 sites in United States, Argentina and 19 more
- Volunteers
- 83 people
- Sponsor
- Sanofi
Giant Cell Arteritis
Tocilizumab Plus a Short Prednisone Taper for GCA
This is an open-label pilot study of tocilizumab (TCZ) 162 mg weekly administered subcutaneously for 52 weeks in combination with 8 weeks of oral prednisone.
- Trial name
- NCT03726749
- Testing
- Tocilizumab, Prednisone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Acute Coronary Syndromes (ACS)
Association Between SYNTAX Score and Leukoglycemic Index In Patients Wiht Acute Coronary Syndrome
This study looks at people who come to the hospital with acute coronary syndrome, a serious heart condition. When these patients first arrive, doctors take routine blood tests.
- Trial name
- NCT07276256
- Testing
- leukoglycemic index calculation
- Where
- Turkey (Türkiye)
- Volunteers
- 552 people
- Sponsor
- Kırıkkale University